BeiGene | Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta as Maintenance Therapy in Chinese Patients With High-risk Neuroblastoma

Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participants With High-Risk Neuroblastoma

Beigene Study ID

BGB-dinutuximab beta-101

ClinicalTrials.gov ID

NCT05373901

China Drug Trials ID

CTR20221154

Sex: All

Age: 12 Months / N/A

Study Protocol Statistical Analysis Plan

Sex: All

Age: 12 Months / N/A

Study Protocol Statistical Analysis Plan